Research ArticleExperimental Studies

Recombinant Interleukin-2 Enhanced the Antitumor Effect of ADV/RSV-HSV-tk/ACV Therapy in a Murine Bladder Cancer Model

SHUJI TERAO, TOSHIRO SHIRAKAWA, KAZUMASA GODA, SADAO KAMIDONO, MASATO FUJISAWA and AKINOBU GOTOH
Anticancer Research July 2005, 25 (4) 2757-2760;

Article Information

vol. 25 no. 4 2757-2760
PubMed 
16080522
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 30, 2005
  • Accepted May 26, 2005
  • Published online July 1, 2005.
Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. SHUJI TERAO1,2,
  2. TOSHIRO SHIRAKAWA1,3,
  3. KAZUMASA GODA2,
  4. SADAO KAMIDONO2,
  5. MASATO FUJISAWA2 and
  6. AKINOBU GOTOH1,3
  1. 1International Center for Medical Research and Treatment, Kobe University School of Medicine
  2. 2Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine
  3. 3Department of Clinical Genetics, Kobe University Hospital, Japan
  1. Correspondence to: Akinobu Gotoh, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Tel: +81 78 382 5708, Fax: +81 78 382 5715, e-mail: terao{at}med.kobe-u.ac.jp

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Recombinant Interleukin-2 Enhanced the Antitumor Effect of ADV/RSV-HSV-tk/ACV Therapy in a Murine Bladder Cancer Model
SHUJI TERAO, TOSHIRO SHIRAKAWA, KAZUMASA GODA, SADAO KAMIDONO, MASATO FUJISAWA, AKINOBU GOTOH
Anticancer Research Jul 2005, 25 (4) 2757-2760;
Twitter logo Facebook logo Mendeley logo

Jump to section